drugset / Trial / NCT01004822
A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
Timeline
- Start
- 2010-03
- Primary completion
- 2014-05
- Completion
- 2014-05
Outcome
Outcome not reported
Stopped: “See termination reason in detailed description.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVX-241 | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 3 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 6 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 12 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 15 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 18 mg/kg | Intravenous |
| Subject | CVX-241 | Protein / enzyme biologic | 25 mg/kg | Intravenous |